When compared to placebo, adjuvant durvalumab did not lead to significant DFS in stage IB (≥ 4 cm)-IIIA NSCLC in those with a PD-L1 expression of 25% or more following surgical resection. The gene discussed is CD274; the disease is non-small cell lung carcinoma.